Study title:
Administración de eritromicina intraparto para la interrupción de la transmisión vertical del Ureaplasma urealyticum y su posible relación con el desarrollo de displasia broncopulmonar en neonatos de menos de 32 semanas de edad gestacional. Proyecto de estudio multicéntrico. (Administration of intrapartum erythromycin for the interruption of the vertical transmission of Ureaplasma urealyticum and its possible relation to the development of bronchopulmonary dysplasia in neonates with less than 32 weeks gestation. Multicenter study). Salcedo Abizanda S, Cabero Roura L, Andreu Domingo A, Lucaya Layret J, Perapoch López J, Casellas Caro M, Fernández Pérez F, Campins Martí M, Torán Fuentes N, Peguero Monforte G. Anales españoles de pediatría, {An Esp Pediatr}, Jun 1997, vol. Spec No 1, p. 73 7.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Bacterial Infections and Mycoses [C01]
|
Brands: Please see report |
MAH holders: Please see report, Please see report |
Assessment: |
Active substance: ERYTHROMYCIN |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|